Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Amedisys, Lowers Price Target to $111

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $114 to $111.
byBenzinga Newsdesk
February 21, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $114 to $111.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0